In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002

被引：46

作者：

Bouchillon, SK

Hoban, DJ

Johnson, BM

Stevens, TM

Dowzicky, MJ

Wu, DH

Bradford, PA

机构：

[1] Labs Int Microbiol Studies, Schaumburg, IL 60179 USA

[2] Wyeth Pharmaceut, Infect Dis Grp, St Davids, PA 19426 USA

[3] Wyeth Res, Infect Dis Discovery, Pearl River, NY 10965 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2005年 / 51卷 / 04期

关键词：

tigecycline; VRE; ESBL; MRSA;

D O I：

10.1016/j.diagmicrobio.2004.11.006

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Tigecycline is the first glycylcycline antimicrobial in phase III clinical trials. This study compares the in vitro activity of tigecycline to 12 other predominately broad-spectrum antimicrobials against 3049 recent inpatient isolates from 38 clinical centers in 17 countries. The minimum concentration at which tigecycline inhibited 90% of the isolates for the entire collection, excluding Pseudomonas aeruginosa, was 1 mu g/mL, including vancomycin-resistant enterococci-, extended-spectrum beta-lactamase-, and methicillin-resistant Staphylococcus aureus-resistant phenotypes. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：291 / 295

页数：5

共 12 条

[1] Novel antibacterial agents for the treatment of serious Gram-positive infections
Abbanat, D
Macielag, M
Bush, K
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (03) : 379 - 399
[2] [Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[3] In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases
Biedenbach, DJ
Beach, ML
Jones, RN
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 40 (04) : 173 - 177
[4] Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, CR
Visalli, MA
Projan, SJ
Sum, PE
Bradford, PA
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) : 972 - 978
[5] Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates
Gales, AC
Jones, RN
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) : 19 - 36
[6] Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)
Henwood, CJ
Gatward, T
Warner, M
James, D
Stockdale, MW
Spence, RP
Towner, KJ
Livermore, DM
Woodford, N
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) : 479 - 487
[7] *NAT COMM CLIN LAB, 2003, M2A8 NCCLS
[8] National Committee for Clinical Laboratory Standards, 2003, M100S13 NCCLS
[9] In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)
Petersen, PJ
Jacobus, NV
Weiss, WJ
Sum, PE
Testa, RT
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) : 738 - 744
[10] In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens
Petersen, PJ
Bradford, PA
Weiss, WJ
Murphy, TM
Sum, PE
Projan, SJ
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) : 2595 - 2601

← 1 2 →